Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Cresci

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Plos One|September 15, 2010
A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetesSharon Cresci, Janice M Huss, Amber L Beitelshees, et al.
JACC. Heart Failure|October 19, 2023
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM TrialAndrew Wang, John A Spertus, Daniel M Wojdyla, et al.
Journal of the American College of Cardiology|June 19, 2012
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific mannerSharon Cresci, Gerald W Dorn, Philip G Jones, et al.
Atherosclerosis|August 2, 2015
Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohortsChristopher Labos, Sara C Martinez, Rui Hao Leo Wang, et al.
Journal of Cardiac Failure|December 9, 2024
Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM TrialAndrew Wang, Neal K Lakdawala, Theodore P Abraham, et al.
Circulation. Cardiovascular Imaging|April 8, 2025
Response to Mavacamten in Patients With High Baseline Left Ventricular Filling Pressures in the EXPLORER-HCM TrialSharon Cresci, Richard G Bach, Anjali T Owens, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2013
Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarctionWassef Karrowni, Yan Li, Philip G Jones, et al.
Circulation. Genomic and Precision Medicine|March 27, 2023
Interpreting Incidentally Identified Variants in Genes Associated With Heritable Cardiovascular Disease: A Scientific Statement From the American Heart AssociationAndrew P Landstrom, Anwar A Chahal, Michael J Ackerman, et al.
Circulation|November 14, 2023
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCMSharon Cresci, Richard G Bach, Sara Saberi, et al.
Circulation|September 14, 2011
Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trialSharon Cresci, Jun Wu, Michael A Province, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Plos One|September 15, 2010
A PPARα promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetesSharon Cresci, Janice M Huss, Amber L Beitelshees, et al.
JACC. Heart Failure|October 19, 2023
Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM TrialAndrew Wang, John A Spertus, Daniel M Wojdyla, et al.
Journal of the American College of Cardiology|June 19, 2012
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific mannerSharon Cresci, Gerald W Dorn, Philip G Jones, et al.
Atherosclerosis|August 2, 2015
Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohortsChristopher Labos, Sara C Martinez, Rui Hao Leo Wang, et al.
Journal of Cardiac Failure|December 9, 2024
Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM TrialAndrew Wang, Neal K Lakdawala, Theodore P Abraham, et al.
Circulation. Cardiovascular Imaging|April 8, 2025
Response to Mavacamten in Patients With High Baseline Left Ventricular Filling Pressures in the EXPLORER-HCM TrialSharon Cresci, Richard G Bach, Anjali T Owens, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 23, 2013
Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarctionWassef Karrowni, Yan Li, Philip G Jones, et al.
Circulation. Genomic and Precision Medicine|March 27, 2023
Interpreting Incidentally Identified Variants in Genes Associated With Heritable Cardiovascular Disease: A Scientific Statement From the American Heart AssociationAndrew P Landstrom, Anwar A Chahal, Michael J Ackerman, et al.
Circulation|November 14, 2023
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCMSharon Cresci, Richard G Bach, Sara Saberi, et al.
Circulation|September 14, 2011
Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the bypass angioplasty revascularization investigation 2 diabetes trialSharon Cresci, Jun Wu, Michael A Province, et al.
Pageof 8